A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics.
Authors
Mitchell, Claire LO'Connor, James P B
Roberts, C
Watson, Y
Jackson, A
Cheung, S
Evans, J
Spicer, J
Harris, A
Kelly, C
Rudman, S
Middleton, M
Fielding, A
Tessier, J
Young, H
Parker, G J M
Jayson, Gordon C
Affiliation
Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK. Claire.Mitchell@christie.nhs.ukIssue Date
2011-09
Metadata
Show full item recordAbstract
Cediranib (RECENTIN™) is an oral, highly potent VEGF inhibitor. This study evaluated the effect of food on the pharmacokinetics of cediranib and compared the administration of continual cediranib via two dosing strategies using this as a platform to investigate pharmacodynamic imaging biomarkers.Citation
A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. 2011, 68 (3):631-41 Cancer Chemother PharmacolJournal
Cancer Chemotherapy and PharmacologyDOI
10.1007/s00280-010-1534-3PubMed ID
21120480Type
ArticleLanguage
enISSN
1432-0843ae974a485f413a2113503eed53cd6c53
10.1007/s00280-010-1534-3
Scopus Count
Related articles
- Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.
- Authors: Lassen U, Miller WH, Hotte S, Evans TR, Kollmansberger C, Adamson D, Nielsen DL, Spicer J, Chen E, Meyer T, Brown K, Rafi R, Sawyer MB
- Issue date: 2013 Feb
- Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
- Authors: van Cruijsen H, Voest EE, Punt CJ, Hoekman K, Witteveen PO, Meijerink MR, Puchalski TA, Robertson J, Saunders O, Jürgensmeier JM, van Herpen CM, Giaccone G
- Issue date: 2010 Mar
- Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment.
- Authors: van Herpen CM, Lassen U, Desar IM, Brown KH, Marotti M, de Jonge MJ
- Issue date: 2013 Feb
- Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.
- Authors: Yamamoto N, Tamura T, Yamamoto N, Yamada K, Yamada Y, Nokihara H, Fujiwara Y, Takahashi T, Murakami H, Boku N, Yamazaki K, Puchalski TA, Shin E
- Issue date: 2009 Nov
- Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.
- Authors: Trarbach T, Schultheis B, Gauler TC, Schneider V, Strumberg D, Eberhardt WE, Le Scouiller S, Marotti M, Brown KH, Drevs J
- Issue date: 2012 Oct